Monday, September 21, 2026RSS
Peptide.Wire

The daily wire on therapeutic peptides. Regulatory, research, compounding and the incretin race, condensed.

Trialstirzepatidesleeve gastrectomyobesityclinicaltrials.gov

Trial tests tirzepatide after sleeve gastrectomy for added weight loss

The investigator-sponsored early-phase randomized study, listed as active and not recruiting, began in March 2025 and compares surgery plus tirzepatide with surgery alone.

PR
By Priya Raman · Science Reporter
Sep 21 08:00 ETSource: ClinicalTrials.gov

The wire

  1. 01ClinicalTrials.gov entry NCT06734273, sponsored by Nicholas Skertich, randomizes patients to sleeve gastrectomy with or without tirzepatide, starting 10 March 2025.
  2. 02Endpoints include additional weight loss and changes in type 2 diabetes, hypertension, hyperlipidemia and sleep apnea, plus whether complications and side effects increase versus surgery alone.
  3. 03The study is early phase 1 and investigator-sponsored; no enrollment figure or results are posted, and it is listed as active but not recruiting.

From the source

Randomized Control Trial of Sleeve Gastrectomy With Tirzepatide in Maximizing Weight Loss

NCT06734273 · EARLY_PHASE1 · ACTIVE NOT RECRUITING · Sponsor: Nicholas Skertich · Conditions: Obesity and Obesity-related Medical Conditions.

Read at clinicaltrials.gov
Source URL https://clinicaltrials.gov/study/NCT06734273